Suven Life Sciences' Q3 FY 2025-26 Quarterly Results
- 30 Jan 2026
Result Summary
- Suven Life Sciences Ltd reported a 18.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 72.2%.
- Its expenses for the quarter were up by 31.1% QoQ and 153.8% YoY.
- The net profit increased 31.8% QoQ and increased 160.5% YoY.
- The earnings per share (EPS) of Suven Life Sciences Ltd declined at 4.55 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 5.58 | 4.70 | 3.24 | 18.7% | 72.2% |
Total Expenses | 107.51 | 82.01 | 42.36 | 31.1% | 153.8% |
Profit Before Tax | -101.92 | -77.31 | -39.12 | 31.8% | 160.5% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -101.92 | -77.31 | -39.12 | 31.8% | 160.5% |
Earnings Per Share | -4.55 | -3.48 | -1.79 | 30.7% | 154.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Suven Life Sciences Ltd operates in the pharmaceutical industry, primarily focusing on the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and formulations. The company is recognized for its contributions to the contract research and manufacturing services (CRAMS) sector, which forms a significant part of its business operations. Suven Life Sciences has been engaged in research and development activities, aiming to enhance its product offerings and ensure compliance with global industry standards. Any recent major developments within the company, such as new product launches or strategic partnerships, are not available in this data set.
Revenue
In the third quarter of the fiscal year 2026, Suven Life Sciences Ltd reported a total income of ₹5.58 crores. This represents an 18.7% increase from the previous quarter and a significant 72.2% rise from the corresponding quarter in the previous year. The company's revenue growth over these periods indicates an upward trend in its income generation capabilities. The quarterly comparison highlights an improvement in revenue streams, while the year-over-year comparison underscores substantial growth attributable to either an increase in sales volume, pricing, or both.
Profitability
For Q3FY26, Suven Life Sciences Ltd recorded a profit before tax of negative ₹101.92 crores, indicating a loss. This figure reflects a 31.8% increase in losses compared to the previous quarter, which had a loss of ₹77.31 crores, and a 160.5% increase in losses compared to the same quarter in the previous year, which was ₹39.12 crores. The net profitability also mirrors this trend, with profit after tax remaining the same as the profit before tax due to the absence of tax expenses, indicating consistent net losses. Earnings per share (EPS) for the quarter stood at negative ₹4.55, compared to negative ₹3.48 in the previous quarter and negative ₹1.79 in Q3FY25, reflecting the company's ongoing challenges in achieving profitability.
Operating Metrics
The total expenses for the quarter were reported at ₹107.51 crores, marking a 31.1% increase from the previous quarter and a 153.8% rise from the same quarter in the prior year. This escalation in expenses has significantly impacted the company's financial performance, contributing to the higher losses observed. The data indicates that despite an increase in total income, the proportional rise in expenses has outweighed revenue gains, thereby affecting the overall financial stability. As there is no additional information on specific operating metrics such as debt, liquidity, or asset utilization, it is not possible to calculate financial ratios like P/E ratio, debt-to-equity, or current ratio from the data provided.